HASTINGS PAUL J 4

What Happened

• Paul J. Hastings, a director of enGene Therapeutics, was granted a derivative award covering 31,000 shares on 2026-06-16. The filing reports the acquisition at $0.00 (total $0) and classifies the transaction as a derivative grant (an option award per the footnote).

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-17 (appears timely).
• Instrument: derivative securities (option award) for 31,000 shares; reported price $0.00; reported total $0.
• Vesting: The option vests in full on the earlier of (i) the first anniversary of the vesting commencement date (June 9, 2026) or (ii) the registrant's 2027 annual meeting of shareholders (per footnote).
• Shares owned after transaction: not specified in the provided summary of the filing.
• Filing timeliness: filing date is one day after the transaction date, which generally meets SEC Form 4 timing expectations.

Context

• This was a grant of an option/award, not an open-market purchase or sale. Such awards are commonly part of director compensation and do not equate to an immediate cash investment or sale. The filing shows the grant but does not include exercise/strike price or other option mechanics in the provided excerpt; consult the full Form 4 for complete terms.